Science | Nature | Cell | View More
Natural Products
Tranexamic acid
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Tranexamic acid
Price: $30 / 20mg
CAS No.: 1197-18-8
Catalog No.: CFN90569
Molecular Formula: C8H15NO2
Molecular Weight: 157.21 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source: The leaves of Ginkgo biloba L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Download: COA    MSDS    SDF    Manual
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / $7.0 / In-stock
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Shanghai Institute of Organic C... (China)
  • Korea Food Research Institute(K... (Korea)
  • Guangzhou Institutes of Biomedi... (China)
  • Instituto Politécnico de Bragan?a (Portugal)
  • Sri Sai Aditya Institute of Pha... (India)
  • Ain Shams University (Egypt)
  • Macau University of Science and... (China)
  • Indian Institute of Science (India)
  • Center for protein Engineering ... (Belgium)
  • Research Unit Molecular Epigene... (Germany)
  • University of Cincinnati (USA)
  • More...
Package
Featured Products
Trigonelline

Catalog No: CFN90225
CAS No: 535-83-1
Price: $40/20mg
Monomethyl lithospermate

Catalog No: CFN91005
CAS No: 933054-33-2
Price: $333/10mg
L-Glutamic acid

Catalog No: CFN93108
CAS No: 56-86-0
Price: $30/20mg
Cinnamic aldehyde

Catalog No: CFN90321
CAS No: 14371-10-9
Price: $30/20mg
Calenduloside E

Catalog No: CFN91169
CAS No: 26020-14-4
Price: $268/10mg
Tectoridin

Catalog No: CFN99921
CAS No: 611-40-5
Price: $50/20mg
Eupatilin

Catalog No: CFN90190
CAS No: 22368-21-4
Price: $68/20mg
14-Deoxy-11,12-didehydroandrograph...

Catalog No: CFN98666
CAS No: 42895-58-9
Price: $30/20mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Terpineol

Catalog No: CFN92688
CAS No: 98-55-5
Price: $30/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Tranexamic acid is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments with IC50 of 5 mM. Tranexamic acid appears to be a promising drug for the prevention and treatment of PPH after both vaginal and caesarean delivery, it can reduce mortality due to traumatic bleeding by a third, without apparent safety issues.
Targets: GABA Receptor
In vivo:
Anaesthesia. 2015 Jan;70 Suppl 1:50-3, e18.
The current place of tranexamic acid in the management of bleeding.[Pubmed: 25440395]
There has been an explosion of interest in the ability of Tranexamic acid to reduce morbidity and mortality in surgical and traumatic bleeding.
METHODS AND RESULTS:
Tranexamic acid has been shown to reduce mortality due to traumatic bleeding by a third, without apparent safety issues. It is now clearly established that intravenous Tranexamic acid reduces blood loss in patients with surgical bleeding and the need for transfusion. It can also be used topically to reduce bleeding. Its use is being explored further in large pragmatic trials in traumatic head injury, postpartum haemorrhage and in upper gastro-intestinal haemorrhage. There are few side effects from the use of Tranexamic acid except when administered in high dose where neurological events have been noted, possibly relating to Tranexamic acid interfering with cerebral GABA and glycine receptors. However, clinical studies suggest that there is no increased efficacy in using a higher dose, and that a dose of 1 g intravenously in an adult patient has maximal efficacy, which is not increased by higher doses.
CONCLUSIONS:
The CRASH-2 trauma trial clearly showed no increase in thrombotic events after its use in trauma, indeed there was a significant reduction in myocardial infarction. However, trials of Tranexamic acid in surgery have failed to adequately study its effects on the risk of postoperative venous and possible reduction in arterial thrombo-embolism, and this needs to be the subject of future research.
Arch Orthop Trauma Surg. 2014 Nov;134(11):1609-14.
Intravenous use of tranexamic acid reduces postoperative blood loss in total knee arthroplasty.[Pubmed: 25179896]
Blood transfusion is often required in total knee replacement (TKR); several methods of blood preservation are commonly used but the ideal solution is to reduce the blood loss during and after surgery. Aim of the study was to evaluate the hemostatic efficacy and safety of intravenous use of Tranexamic acid in patients receiving TKR (cemented).
METHODS AND RESULTS:
Forty-five patients after TKR receive treatment with Tranexamic acid (TXA, treatment group), and 45 were managed with fibrin tissue adhesive (control group). Hemoglobin values decrease and transfusions in both groups were recorded. Statistical analysis was performed with Student t test and χ (2) test. A statistical model was elaborated to evaluate together all variables and to underline what data can increase transfusions need. A significant reduction was detected in hemoglobin values in the first 3 days after surgery in the treatment group. The difference in all cases was significant. When Tranexamic acid was administered, the need for transfusions was lower (difference statistically significant). No major adverse events were recorded in our series. The use of autologous blood preparation before surgery led to a higher transfusion rate.
CONCLUSIONS:
Tranexamic acid reduced blood loss in TKR and significantly reduced the blood transfusion need also when compared to fibrin tissue adhesive. The use of Tranexamic acid is safe and in future may avoid preparation of autologous blood unit before surgery with a decrease of cost and medical figures involved.
Br J Anaesth. 2015 Apr;114(4):576-87.
Tranexamic acid for the prevention and treatment of postpartum haemorrhage.[Pubmed: 25571934]
Postpartum haemorrhage (PPH) is a major cause of maternal mortality, accounting for one-quarter of all maternal deaths worldwide. Uterotonics after birth are the only intervention that has been shown to be effective for PPH prevention. Tranexamic acid (TXA), an antifibrinolytic agent, has therefore been investigated as a potentially useful complement to this for both prevention and treatment because its hypothesized mechanism of action in PPH supplements that of uterotonics and because it has been proved to reduce blood loss in elective surgery, bleeding in trauma patients, and menstrual blood loss. This review covers evidence from randomized controlled trials (RCTs) for PPH prevention after caesarean (n=10) and vaginal (n=2) deliveries and for PPH treatment after vaginal delivery (n=1).
CONCLUSIONS:
It discusses its efficacy and side effects overall and in relation to the various doses studied for both indications. TXA appears to be a promising drug for the prevention and treatment of PPH after both vaginal and caesarean delivery. Nevertheless, the current level of evidence supporting its efficacy is insufficient, as are the data about its benefit:harm ratio. Large, adequately powered multicentre RCTs are required before its widespread use for preventing and treating PPH can be recommended.
Clin Orthop Relat Res. 2014 May;472(5):1552-7.
Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.[Pubmed: 24385043]
Systemic Tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical Tranexamic acid in THA has only recently been characterized in a small number of studies. The purpose of this study was to compare (1) the greatest hemoglobin decrease after surgery; (2) transfusion rates; and (3) symptomatic thromboembolic events among patients undergoing THA who did and did not receive topical Tranexamic acid.
METHODS AND RESULTS:
We retrospectively compared 135 patients (154 THAs) who received 10 mL 5% Tranexamic acid added in a topical cocktail solution during surgery between January 2009 and July 2011 with 211 patients (234 THAs) who received only the topical cocktail solution (analgesic and antibiotic agent) between January 2005 and December 2008. Contraindications for the use of Tranexamic acid included a documented history of a venous thromboembolic event, an allergy to Tranexamic acid, thrombophilia, or a high risk of venous thromboembolism based on the guidelines of the American Academy of Orthopaedic Surgeons; the 135 patients who received it during that period represented 99.4% of the patients undergoing THA during that time. We compared changes in Hb, transfusion rates, estimated blood loss, surgical results, and complications between the groups. The transfusion threshold was the same, when the Hb values were < 10 g/dL. Patients were screened for thromboembolic disease if symptoms or signs appeared. Hb decreased less in the Tranexamic acid group (1.87 ± 1.10 g/dL) than in the control group (2.2 ± 1.36 g/dL; p = 0.01) on the first postoperative day. The frequency of transfusion was lower in patients receiving Tranexamic acid (17% as compared with 35% in the control group; p < 0.001). There was only one nonfatal pulmonary embolism in the control group during the study period.
CONCLUSIONS:
Use of topical Tranexamic acid in patients undergoing THA reduces postoperative bleeding and decreases blood transfusion rates. No increase in major complications was identified in patients managed with topical Tranexamic acid. This retrospective study confirms the results of a smaller randomized trial on the same topic by another group.
Tranexamic acid Description
Source: The leaves of Ginkgo biloba L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Ganoderic acid beta

Catalog No: CFN95537
CAS No: 217476-76-1
Price: $413/5mg
Sophoraflavone A

Catalog No: CFN95510
CAS No: 105594-08-9
Price: $318/10mg
1,2-Epoxy-10(14)-furanogermacren-6...

Catalog No: CFN95214
CAS No: 383368-24-9
Price: $318/10mg
Isocucurbitacin D

Catalog No: CFN95326
CAS No: 68422-20-8
Price: $318/5mg
3-Hydroxymollugin

Catalog No: CFN95424
CAS No: 154706-45-3
Price: $368/5mg
Isomargaritene

Catalog No: CFN95304
CAS No: 64271-11-0
Price: $318/10mg
Neochlorogenic acid methyl ester

Catalog No: CFN95190
CAS No: 123410-65-1
Price: $198/5mg
Polygalin J

Catalog No: CFN95175
CAS No: N/A
Price: $318/5mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 6.3609 mL 31.8046 mL 63.6092 mL 127.2184 mL 159.023 mL
5 mM 1.2722 mL 6.3609 mL 12.7218 mL 25.4437 mL 31.8046 mL
10 mM 0.6361 mL 3.1805 mL 6.3609 mL 12.7218 mL 15.9023 mL
50 mM 0.1272 mL 0.6361 mL 1.2722 mL 2.5444 mL 3.1805 mL
100 mM 0.0636 mL 0.318 mL 0.6361 mL 1.2722 mL 1.5902 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Animal Research:
Am J Vet Res. 2014 Dec;75(12):1099-103.
Efficacy and safety of tranexamic acid as an emetic in dogs.[Pubmed: 25419810]
To determine dose dependency of Tranexamic acid-induced emesis and the time course of the antifibrinolytic potency of Tranexamic acid in dogs.
METHODS AND RESULTS:
10 Beagles.In a dose-escalating experiment, ascending doses of Tranexamic acid (10, 20, and 30 mg/kg, IV) were administered at 5-minute intervals until vomiting was observed. In a separate single-dose experiment, ascending doses of Tranexamic acid (20, 30, 40, and 50 mg/kg, IV) were administered at 1-week intervals until vomiting was observed. Time to onset of vomiting and number of vomiting episodes were measured in both experiments. In a coagulation experiment, a single 50 mg/kg bolus of Tranexamic acid was administered, and blood was obtained 1 hour before and 20 minutes, 3 hours, and 24 hours after administration. Antifibrinolytic potency of Tranexamic acid was evaluated by use of a modified rotational thromboelastography method. Tranexamic acid induced vomiting in a dose-dependent manner. Vomiting frequency was ≤ 2 episodes, and vomiting concluded ≤ 250 seconds after administration. Antifibrinolytic potency of Tranexamic acid was significantly higher at 20 minutes following administration, but not different by 24 hours, when compared with the potency measured before administration. No adverse effects were observed in any experiment.
CONCLUSIONS:
IV administration of Tranexamic acid induced emesis in a dose-dependent manner. The antifibrinolytic potency of Tranexamic acid decreased in a time-dependent manner and was resolved ≤ 24 hours after administration. Further studies are warranted to investigate the emetic and other adverse effects of Tranexamic acid in dogs of various breeds and ages.
Trigonelline

Catalog No: CFN90225
CAS No: 535-83-1
Price: $40/20mg
Monomethyl lithospermate

Catalog No: CFN91005
CAS No: 933054-33-2
Price: $333/10mg
L-Glutamic acid

Catalog No: CFN93108
CAS No: 56-86-0
Price: $30/20mg
Cinnamic aldehyde

Catalog No: CFN90321
CAS No: 14371-10-9
Price: $30/20mg
Calenduloside E

Catalog No: CFN91169
CAS No: 26020-14-4
Price: $268/10mg
Tectoridin

Catalog No: CFN99921
CAS No: 611-40-5
Price: $50/20mg
Eupatilin

Catalog No: CFN90190
CAS No: 22368-21-4
Price: $68/20mg
14-Deoxy-11,12-didehydroandrograph...

Catalog No: CFN98666
CAS No: 42895-58-9
Price: $30/20mg
Uridine

Catalog No: CFN97000
CAS No: 58-96-8
Price: $30/20mg
Terpineol

Catalog No: CFN92688
CAS No: 98-55-5
Price: $30/20mg
Tags: buy Tranexamic acid | Tranexamic acid supplier | purchase Tranexamic acid | Tranexamic acid cost | Tranexamic acid manufacturer | order Tranexamic acid | Tranexamic acid distributor